Now, the Florida-based drugmaker has parried another Firdapse challenger in Teva Pharmaceuticals, which had hoped to market a generic version of the Lambert-Eaton myasthenic syndrome (LEMS ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin ...

Catalyst Pharmaceuticals, Inc. has reached a Settlement Agreement with Teva Pharmaceuticals regarding patent litigation over the generic version of FIRDAPSE® (amifampridine) 10 mg tablets.

(MENAFN- GlobeNewsWire - Nasdaq) As Part of the Settlement, Teva Receives a License to market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE ...

This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE ® ...

This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic ...

This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE ...